An observational study in Pneumonia and Orotracheal Intubation, sponsored by University Hospital, Clermont-Ferrand. Not yet recruiting at 6 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by University Hospital, Clermont-Ferrand · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 138 studies in Pneumonia with a site in France — 18 open to participants now, 20 under way, 3 of them phase 3. Pneumonia · France.
Among the 138 studies in Pneumonia with a site in France, this one is the 15th largest by planned enrollment of the 56 observational ones that give a count, is one of 2 that started in 2026, is one of 56 observational ones, reaches primary completion later than 12 of the 19 other live ones, and was the 137th registered.
1,569 studies on the registry are indexed under Pneumonia; 267 are open to participants now.
Browse Pneumonia studies →18 of the 138 studies in Pneumonia with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Centre Hospitalier Sud Francilien · Sites in France
Ages 18+
Pfizer · Sites in France, United States, Argentina and 15 more countries
Ages 18+
University Hospital, Montpellier · Sites in France
Ages 18+
University Hospital, Caen · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 159 Pneumonia studies recruiting now, 84 (53%) set no upper age limit and 48 (30%) stop at 75 or younger; 40 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
138 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 24 · Phase 3 32 · Phase 4 3
First in 2003; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 600 is above the median of 255 across 537 observational studies indexed under Pneumonia.
Median enrollment 161 across the 79 interventional studies, 227 across the 56 observational. Of the 99 that completed or were terminated, 14 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 138 have an industry lead sponsor. The 10 most frequent:
University Hospital, Clermont-Ferrand is the lead sponsor of 859 studies on the registry; 177 are open to participants now.
University Hospital, Clermont-Ferrand has 1 study filed under Pneumonia — fewer than ten, so there is no comparison to draw.
3 of the studies in Pneumonia with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT07439146University Hospital, Clermont-FerrandRisk of Pneumonia in Intubated Patients in Emergency Situations | 2026-12-31 |
| NCT06916481Assistance Publique - Hôpitaux de ParisDefinition of Sub-phenotypes of Pneumonia Based on the Respiratory Microbiome Composition to Predict Microbial and Clinical Treatment Failures | 2027-09-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 138 studies in Pneumonia with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Orotracheal intubation in emergency medicine is a vital procedure for ensuring adequate oxygenation and ventilation in patients with respiratory distress or in shock. However, this procedure exposes patients to complications such as pneumonia. In the matter of fact, the urgency of the procedure means that it is not possible to wait until the patient's stomach is empty. Pneumonia significantly increase patient morbidity and mortality. Therapeutic management must be early and appropriate to improve the patient's prognosis.
The aim of this study is to compare the rate of pneumonia occurring in patients intubated in emergency situations with that in patients intubated in non-emergency situations in all 2024. Health data will only collected from patient's medical records.
Study population is patient intubated in emergency situation and patients intubated in non-emergency situation following to the admission of intensive care in 2024.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Health data will be collected only with medical's record of intubated patients in emergency situation in 2024.
Health data will be collected only with medical's record of intubated patients in non emergency situation in 2024.
Pneumonia rate in 48 hours after the start of orotracheal intubation.
Rate of pneumonia occuring within 48 hours of the start of orotracheal intubation.
Time frame: Hour 48
Pneumonia rate occuring 48 hours after the start of orotracheal intubation.
Rate of pneumonia occuring more than 48 hours after the start of orotracheal intubation.
Time frame: 3 months
Duration of mechanical ventilation
Duration of mechanical ventilation
Time frame: Up to the end of mechanical ventilation (assessed up to 1 month)
Duration of stay in intensive care
Duration of stay in intensive care
Time frame: Up to intensive care discharge (assessed up to 1 month)
Duration of hospital stay
Duration of hospital stay
Time frame: Up to hospital discharge (assessed up to 3 months)
Mortality rate
Mortality rate
Time frame: Inclusion + 1 year
Type of bacteria responsible for pneumonia
The bacterial species responsible for pneumonia will be identified using biological samples (blood, urine, bronchial secretions) taken from patients in both groups. The identification of bacterial species will be carried out in the laboratory.
Time frame: The day of the diagnosis of pneumonia (assessed up to 1 month)
Type of antibiotic administered for pneumonia
Type of antibiotic administered for pneumonia in each group
Time frame: Up to the last day of antibiotic treatment (assessed up to 3 months)
Antibiotic doses administered for pneumonia
Comparison of antibiotic doses in g or mg administered in each group
Time frame: Up to the last day of antibiotic treatment (assessed up to 3 months)
Duration of antibiotic treament for pneumonia
Duration of antibiotic treament for pneumonia in each group
Time frame: Up to the last day of antibiotic treatment (assessed up to 3 months)
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Feb 2026; primary completion for Dec 2026, 10 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Clermont-Ferrand →